By Stephen Nakrosis
Galapagos NV said Paul Stoffels, the company's chair and chief executive officer, intends to retire as CEO upon appointment of a successor, but plans to continue serving as chair.
The board will search for a successor to Stoffels, with the successor CEO expected to be hired in the next 12 months.
The company also said Henry Gosebruch, who was most recently president and CEO at Neumora, was appointed by the board to serve as the founding CEO of a newly created company which will be spun off. The new company will initially be funded with about EUR2.45 billion ($2.81 billion) in cash and cash equivalents. The new company will focus on building a pipeline of "innovative medicines with demonstrated proof-of-concept and the potential to elevate standard-of-care for patients through one or more transformative transactions," according to Galapagos.
Prior to Neumora, Gosebruch was EVP and chief strategy officer at AbbVie, and before that worked at J.P. Morgan, Galapagos said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 21, 2025 16:53 ET (20:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。